Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
Monday, January 11, 2016 - 14:31
in Health & Medicine
40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.